Myasthenia gravis and concurrent myositis following PD-L1 checkpoint inhibitor for non-small cell lung cancer.
Chun Seng PhuaAri MuradClare FraserVictoria BrayCecilia Cappelen-SmithPublished in: BMJ neurology open (2020)
Clinicians using ICIs should have a high index of suspicion for ICI-induced MG and concurrent myositis as disease can be severe and is associated with high mortality rates.
Keyphrases
- myasthenia gravis
- locally advanced
- interstitial lung disease
- dna damage
- high glucose
- early onset
- cardiovascular events
- cell cycle
- systemic sclerosis
- cardiovascular disease
- squamous cell carcinoma
- rheumatoid arthritis
- type diabetes
- radiation therapy
- coronary artery disease
- idiopathic pulmonary fibrosis
- oxidative stress
- rectal cancer